当前位置: 首页 >> 检索结果
共有 7369 条符合本次的查询结果, 用时 4.5868517 秒

261. Cardiac MRI optimizes risk stratification accuracy in connective tissue disease-associated pulmonary arterial hypertension: a retrospective cohort study.

作者: Yue Zhang.;Xiaohui Wang.;Xiaoxuan Sun.;Zhangdi Zhou.;Dongyu Li.;Yixin Zhang.;Qi Hu.;Linwei Shan.;Jiayi Dai.;Huangshu Ye.;Lei Zhou.;Yinsu Zhu.;Qiang Wang.
来源: Rheumatology (Oxford). 2025年
The primary objective of this study is to investigate the potential of cardiovascular magnetic resonance (CMR) parameters to augment prognostic evaluation in patients with connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH).

262. Association of oral opioid usage and mortality in patients with inflammatory arthritides: a Korean nationwide cohort study.

作者: Sung Soo Ahn.;Minkyung Han.;Inkyung Jung.;Chi Young Kim.
来源: Rheumatology (Oxford). 2025年
Recent studies have raised concerns regarding usage of opioids, a class of drugs widely used for managing chronic pain in musculoskeletal disorders; however, its potential risks remain incompletely understood. This study aimed to evaluate the association between oral opioid use and mortality in a nationwide inflammatory arthritides (IA) cohort.

263. Aseptic meningitis in the setting of giant cell arteritis (GCA): a case report.

作者: Lehashenee Thirukumar.;Robin Sia.;Justin Jackson.;John Burston.
来源: BMC Rheumatol. 2025年9卷1期29页
Giant cell arteritis (GCA) is a vasculitis primarily affecting medium- and large-sized arteries. The diagnosis may be challenging and lead to delays in treatment. Cerebrospinal fluid (CSF) pleocytosis is an uncommon association but may occur due to central nervous system (CNS) vasculitis or pachymeningitis. We describe a case fulfilling the criteria for diagnosing GCA, associated with CSF pleocytosis and normal neuroimaging.

264. Diagnostic, research, and real-life effect of the 2023 EULAR-ACR classification criteria for antiphospholipid syndrome.

作者: Karen Schreiber.;Silvia Aguilera.;Olga Amengual.;Hannah Cohen.;Danieli Castro Oliveira De Andrade.;Alí Duarte-García.;Maria Gerosa.;Catherine Nelson-Piercy.;Massimo Radin.;Luigi Raio.;Savino Sciascia.
来源: Lancet Rheumatol. 2025年7卷5期e368-e376页
The role of classification criteria is particularly important in rheumatic diseases compared with other medical disorders, as the complexity and overlapping symptoms of these conditions make diagnosis challenging. Moreover, the absence of established diagnostic criteria further complicates diagnosing patients. Classification criteria can assist health-care professionals and patients as a diagnostic aid. However, classification criteria are developed for research purposes to standardise populations in clinical trials and observational studies of rheumatic diseases and not for diagnosing patients. Introduction of the 2023 American College of Rheumatology-European Alliance of Associations for Rheumatology (ACR-EULAR) antiphospholipid syndrome classification criteria underscores the important distinction between meeting these criteria and being diagnosed with the condition-a differentiation essential in both clinical practice and research. Although the 2023 ACR-EULAR antiphospholipid syndrome classification criteria improved precision in classification of pregnant individuals with antiphospholipid syndrome, which ultimately should lead to better outcomes and care for these patients, the updated criteria should not be used as diagnostic criteria in routine clinical practice. In this Personal View, we examine the possible effect of the 2023 ACR-EULAR antiphospholipid syndrome classification criteria, with a particular focus on the pregnancy-related aspects of the syndrome.

265. The state of data sharing in rheumatology: a systematic review of top journal practices.

作者: Michelle Pham.;Eddy Bagaruka.;Eli Oldham.;Mahad Chaudhry.;Jacob Duncan.;Taylor Gardner.;Annes Elfar.;Eli Paul.;Alicia Ito Ford.;Matt Vassar.
来源: Rheumatology (Oxford). 2025年
To evaluate data sharing statement (DSS) inclusion within rheumatology clinical studies published over the past four years in ten top rheumatology journals.

266. Identification and characteristics of patients with axial psoriatic arthritis: clinical, phenotypic, and imaging associations.

作者: Konstantinos D Vassilakis.;Charalampos Papagoras.;Sousana Gazi.;Evangelia Mole.;Michael Krikelis.;Paraskevi V Voulgari.;Evripidis Kaltsonoudis.;Nikolaos Koletsos.;Pelagia Katsimpri.;Dimitrios Boumpas.;Dimitrios Katsifis-Nezis.;Nikolaos Kougkas.;Maria Boutel.;Theodoros Dimitroulas.;Petros P Sfikakis.;Maria G Tektonidou.;Artemis Galani.;Nikolaos Michalakeas.;Dimitrios P Bogdanos.;Theodora Simopoulou.;Christos Koutsianas.;Evgenia Mavrea.;Gkikas Katsifis.;Konstantinos Kottas.;Maria Konsta.;Evangelia Kataxaki.;Eleni Kalavri.;Kalliopi Klavdianou.;Charalampos Sfontouris.;Dimitrios Daoussis.;George Iliopoulos.;Ilias Bournazos.;Dimitrios Karokis.;Constantinos Georganas.;Dimos Patrikos.;Dimitrios Vassilopoulos.;George E Fragoulis.
来源: Rheumatology (Oxford). 2025年
To present the clinical and imaging characteristics of patients with Axial Psoriatic Arthritis (PsA) and to identify possible subtypes.

267. Evolution and trajectory of B-cell targeted therapies in rheumatic diseases.

作者: Lucy Marie Carter.;Michael R Ehrenstein.;Edward M Vital.
来源: Lancet Rheumatol. 2025年7卷5期e355-e367页
Aberrant B-cell function, which could arise from various underlying causes, is central to the pathogenesis of diverse autoimmune rheumatic diseases. B cells remain the only cell type to be specifically therapeutically targeted through depletion and have the only therapy with a routinely available flow cytometric biomarker of treatment. Since first use and subsequent licensing for rheumatoid arthritis, rituximab has had a transformative impact on patients globally and across the rheumatic diseases. Further insights from B-cell-activating factor (BAFF) blockade with belimumab in systemic lupus erythematosus have followed. Examination of B-cell depletion, clinical outcomes, and re-emergent disease after treatment have deepened our understanding of the identity, detailed phenotype, biology, and kinetics of the B-cell subsets that are central to disease. This Review reflects on 20 years of clinical and translational insights drawn from B-cell targeted therapies for adult autoimmune rheumatic diseases, and highlights how these therapies have informed an exciting new era of future therapeutic developments.

268. Obinutuzumab effective for lupus nephritis.

作者: Sarah Onuora.
来源: Nat Rev Rheumatol. 2025年21卷4期193页

269. Unwarranted escalation of care for back pain: a dilemma for emergency health services.

作者: Simon Vella.;Peter Youssef.;Chris Maher.;Gustavo Machado.
来源: Lancet Rheumatol. 2025年7卷4期e229-e231页

270. Relapse of mixed cryoglobulinemia despite sustained virologic response with nucleotide analogues therapy in chronic hepatitis B.

作者: Cesare Mazzaro.;Riccardo Bomben.;Luca Picco.;Ada Zanier.;Ornella Schioppa.;Valter Gattei.
来源: Rheumatology (Oxford). 2025年

271. Identification of biomarkers and immune infiltration associated with sexes in systemic sclerosis: a bioinformatics and machine learning.

作者: Yi'an Tian.;Shuyu Chen.;Bingrui Yu.;Yu Chen.;Siyuan Jia.;Huifang Wang.;Li Zhu.;Zhaofang Tian.
来源: Rheumatology (Oxford). 2025年
This study aimed to identify key candidate genes associated with the sexes of patients with systemic sclerosis (SSc).

272. Impact of gastrointestinal and psychological symptoms on disease activity and functional impairment in patients with spondyloarthritis: a cross-sectional study.

作者: Ángelo Arzuaga-Hernández.;Omar-Javier Calixto.;Oscar Gómez.;Juliette De Ávila.;Julián Andrés Sucerquia-Quintero.;Juan Manuel Bello-Gualtero.;Cristian Flórez-Sarmiento.;Wilson Bautista-Molano.;Consuelo Romero-Sánchez.
来源: BMC Rheumatol. 2025年9卷1期28页
Spondyloarthritis (SpA) exhibits predominantly musculoskeletal symptoms but also significant gastrointestinal (GI) and psychological manifestations. Subclinical gut inflammation is common in SpA, with frequent symptoms such as abdominal pain and diarrhea. Psychological issues like depression and anxiety are also prevalent, with a negative impact on quality of life. This study aimed to evaluate the presence of GI and psychiatric symptoms in SpA patients without inflammatory bowel disease (IBD) and their association with disease characteristics.

273. Stem and progenitor cells in the synovial joint as targets for regenerative therapy.

作者: Anke J Roelofs.;Jessica J McClure.;Elizabeth A Hay.;Cosimo De Bari.
来源: Nat Rev Rheumatol. 2025年21卷4期211-220页
Damage to articular cartilage, tendons, ligaments and entheses as a result of trauma, degeneration or inflammation in rheumatic diseases is prevalent. Regenerative medicine offers promising strategies for repairing damaged tissues, with the aim of restoring both their structure and function. While these strategies have traditionally relied on tissue engineering approaches using exogenous cells, interventions based on the activation of endogenous repair mechanisms are an attractive alternative. Key to advancing such approaches is a comprehensive understanding of the diversity of the stem and progenitor cells that reside in the adult synovial joint and how they function to repair damaged tissues. Advances in developmental biology have provided a lens through which to understand the origins, identities and functions of these cells, and insights into the roles of stem and progenitor cells in joint tissue repair, as well as their complex relationship with fibroblasts, have emerged. Integration of knowledge obtained through studies using advanced single-cell technologies will be crucial to establishing unified models of cell populations, lineage hierarchies and their molecular regulation. Ultimately, a more complete understanding of how cells repair tissues in adult life will guide the development of innovative pro-regenerative drugs, which are poised to enter clinical practice in musculoskeletal medicine.

274. Comment on: Impact of baseline proteinuria level on long-term outcomes in lupus nephritis.

作者: Takeshi Zoshima.
来源: Rheumatology (Oxford). 2025年

275. Comment on: Impact of baseline proteinuria level on long-term outcomes in lupus nephritis: Reply.

作者: Fadi Kharouf.;Qixuan Li.;Laura P Whittall Garcia.;Dafna D Gladman.;Zahi Touma.
来源: Rheumatology (Oxford). 2025年

276. Value of lung ultrasonography for screening interstitial lung disease in patients with rheumatoid arthritis.

作者: Sébastien Ottaviani.;Marie-Pierre Debray.;Raphael Borie.;Marine Forien.;Esther Ebstein.;Pierre-Antoine Juge.;Bruno Crestani.;Philippe Dieudé.
来源: Rheumatology (Oxford). 2025年
Interstitial lung disease (ILD) is a common complication of rheumatoid arthritis (RA) usually diagnosed with high-resolution CT (HRCT), but emerging data suggest the interest of lung ultrasonography (LUS) for screening RA-ILD. This study aimed to determine the ability of LUS to screen ILD in RA.

277. The use of combination advanced therapies in psoriatic arthritis: results from a UK multi-centre audit.

作者: Hannah Jethwa.;Tania Gudu.;Laura C Coates.;Philip S Helliwell.;William Tillett.;Abdalla Abuelmagd.;Rajinder S Andev.;Madiha Ashraf.;Tanya Baqai.;Ernest Choy.;Dhivya Das.;Nicola Gullick.;Catherine Heighton.;Alison Kinder.;Ramasharan Laxminarayan.;Gayatri Mittal.;Penelope Morris.;Sandeep Mukherjee.;Anupama Nandagudi.;Satyapal Rangaraj.;Poonam Sharma.;Hoda Temple.;Beverly Traub.;Vishal Paisal.;Ryan Hum.;Arani Vivekanantham.;Robert Wilson.;Deepak Jadon.
来源: Rheumatology (Oxford). 2025年64卷5期3173-3176页

278. Patient perspectives on the impact of appearance and weight changes attributed to systemic glucocorticoid treatment of rheumatic diseases.

作者: Stephanie J Lax.;Emma Dures.;Susan Bridgewater.;Christine Silverthorne.;Vivien Lowndes.;Pam Richards.;Andreia Ferreira.;Michael A Shepherd.;Jill Dawson.;Catherine Hill.;Susan Goodman.;Sarah L Mackie.;Mwidimi Ndosi.;Fiona A Pearce.;Joanna C Robson.
来源: Rheumatology (Oxford). 2025年
To explore patients' perspectives on the impact of appearance changes attributed to glucocorticoid treatment.

279. Belimumab concentrations and immunogenicity in relation to drug effectiveness and safety in SLE within a Swedish real-world setting.

作者: Alvaro Gomez.;Tomas Walhelm.;Floris C Loeff.;Andreas Jönsen.;Dionysis Nikolopoulos.;Bryan van den Broek.;Anders A Bengtsson.;Annick de Vries.;Theo Rispens.;Christopher Sjöwall.;Ioannis Parodis.
来源: Rheumatology (Oxford). 2025年
Studies supporting therapeutic drug monitoring to biopharmaceuticals in systemic lupus erythematosus (SLE) are scarce. We aimed to assess anti-drug antibody (ADA) occurrence in belimumab-treated SLE patients and associations between belimumab concentrations and clinical response, serological outcomes, and adverse events.

280. Remission is the ambition: Can remission rates for new patients with rheumatoid arthritis finally be improved, at minimal cost?

作者: Sana Sharrack.;Andrea Di Matteo.;Kulveer Mankia.;Shouvik Dass.;Paul Emery.
来源: Rheumatology (Oxford). 2025年
共有 7369 条符合本次的查询结果, 用时 4.5868517 秒